Unitree Finalizes Underwriting as Late-July STAR Market Debut Comes Into View宇树科技完成承销安排，STAR市场七月底上市在即

The number that matters this week is not 42 billion yuan. It is 10 percent — the minimum public float that produces that valuation as a floor, not a ceiling. When Unitree Robotics prices its shares on Shanghai's STAR Market, possibly before Friday, it will hand the global robotics industry something it has never had: a liquid, exchange-derived valuation anchor for pure-play embodied AI. Watch the order book, not the press release.

The regulatory path is clear. The China Securities Regulatory Commission granted registration approval on July 3, 2026. CITIC Securities, the lead underwriter, is now finalizing pricing and coordinating share subscriptions. Caixin Global confirmed the approval and the 4.2 billion yuan (~$618 million) target raise on the day it landed. South China Morning Post has since framed the listing as a stress-test for the venture valuations flooding into Chinese robotics — a framing that is more useful than most.

The prospectus numbers are the story. Unitree reported 1.7 billion yuan in 2025 revenue, a 335 percent year-on-year increase, with a gross margin of 60.13 percent on core businesses and an adjusted net profit of 590 million yuan. Those margins are software-company territory for a firm that ships physical robots. The filing documents a structural inflection: humanoid revenue overtook quadruped revenue during 2025, with over 5,500 humanoid units shipped — a figure the company uses to claim a 32.4 percent global share of humanoid unit shipments. That share claim comes from Unitree's own prospectus, which is the only place it appears. Take it as a baseline for argument, not settled fact.

Governance structure: founder Wang Xingxing retains 68.78 percent of voting rights post-offering. That concentration is a feature for insiders who trust his product roadmap and a risk factor for everyone else. STAR Market rules permit weighted voting rights for tech founders, so the structure is compliant — but institutional investors pricing the float will be buying a minority stake in a founder-controlled entity at a moment when humanoid robotics is still more roadmap than revenue base. The 590 million yuan in adjusted net profit is real; the word adjusted always warrants a line-by-line read of what was excluded.

The strategic significance extends well beyond Unitree itself. This is the first pure-play embodied-AI listing on any major exchange, anywhere. Boston Dynamics remains private. Figure and Physical Intelligence have not filed. When STAR Market sets a price, it creates a comparables benchmark that every subsequent fundraising deck — in Shanghai, San Francisco, and Seoul — will reference. Chinese policy institutions will also be watching: the listing validates the state's multi-year push to treat humanoid robotics as a strategic manufacturing sector, not merely a research curiosity.

What the prospectus does not resolve: customer concentration. Rapid revenue growth at this velocity in Chinese industrial tech frequently relies on a small number of anchor buyers, often state-linked enterprises. The filing's disclosure on customer composition is the passage worth reading carefully — more carefully than the headline growth rate. Similarly, the 5,500 unit shipment figure conflates demonstration units, pilot deployments, and full commercial contracts in ways the prospectus language may or may not distinguish. RoboZaps has flagged the listing in its weekly tracker but does not drill into the filing itself.

The pricing session is the immediate event to monitor. STAR Market IPOs in this size range typically see significant retail oversubscription — China's individual investors have shown consistent appetite for anything tagged to AI and robotics. That demand can inflate first-day prices and create a secondary-market correction that obscures the underlying business trajectory. If the stock opens at a substantial premium to the issue price and then retreats within the first two weeks, that pattern will tell you more about domestic retail sentiment than about Unitree's competitive position.

Watch for three things in the coming days: the final issue price relative to the 42 billion yuan implied valuation (any discount signals institutional pushback); the disclosed subscriber breakdown between institutional and retail tranches; and whether Wang Xingxing makes any public statements about international revenue targets — the prospectus's geographic revenue split is the number most relevant to anyone assessing Unitree against non-Chinese rivals. The sentence in the filing, not the roadshow speech, is where this story lives.

Unitree Robotics is now finalizing its underwriting plan, share pricing, and subscription mechanics for a potential debut on Shanghai's STAR Market as early as late July, according to SCMP. The China Securities Regulatory Commission approved the company's IPO registration on July 2, a process that took only 104 days from filing acceptance — the fastest review record since STAR Market's pre-review mechanism launched.

The offering targets 4.2 billion yuan ($618 million) via at least 40.4 million shares — a minimum 10 percent stake — implying an initial valuation of roughly 42 billion yuan. Unitree posted 2025 revenue of 1.69 billion yuan and a 35 percent net profit margin, an outlier profitability profile in a sector where most peers are still burning cash.

Analysts are watching the debut as a sector-wide valuation anchor. Wanlian Securities analyst Cai Zilin noted that 2026 is 'a critical window to corroborate mass production and adoption' for humanoid robots. Deep Robotics and Leju Robotics are among the competitors also pursuing A-share listings behind Unitree.

AgiBot, the Shanghai humanoid robot company that produced its 10,000th unit in March 2026, is pursuing a Hong Kong IPO at a valuation of HK$40–50 billion (roughly US$5.1–6.4 billion), according to Reuters sources. The company plans to issue 15–25% of shares in the offering, which would be one of the largest Hong Kong tech listings of 2026.

The move puts AgiBot in direct public-market competition with Unitree Robotics, which received CSRC approval on July 3 for a Shanghai STAR Market listing targeting 4.2 billion yuan (US$619 million) — implying a comparable valuation of around 42 billion yuan. Unitree is currently finalising underwriting and pricing, with a potential debut as early as late July.

EngineAI has also filed for a Hong Kong listing, explicitly citing Unitree's valuation as a sector benchmark. In the first half of 2026, China's embodied-intelligence sector recorded 288 financing events totalling over 46 billion yuan in disclosed funding, per IT Juzi data — signalling that the primary-to-secondary market transition is now fully underway.

A Morgan Stanley China industrials note — cited this week in Bloomberg reporting — states that 'funds from most of the Chinese humanoids' IPOs will go toward R&D, especially robot models,' drawing a clear distinction between the capital-raise rationale and near-term commercial revenue. The bank's head of China industrials research writes that humanoid listings are 'one step closer,' and that market interest will be ignited in the second half of 2026.

The caution is warranted by market data: a gauge of humanoid robot stocks has fallen roughly 12% year-to-date in 2026, after registering a 47% gain in 2025. The ChinaAMC CSI Robot ETF has seen net outflows for most of the year. Many robotics firms are expected to burn cash for years before reaching meaningful revenue.

The IPO pipeline includes category leader Unitree and LimX Dynamics, which closed a $200 million pre-IPO round earlier this month. The Morgan Stanley note aligns with a broader investor pattern: enthusiasm for the sector's long-term potential sitting alongside skepticism about near-term fundamentals.

Unitree's IPO prospectus, filed ahead of its imminent STAR Market debut, discloses that adjusted net profit fell 52.55% year-on-year in the first quarter of 2026 — a notable deceleration for a company that posted five consecutive profitable years since 2020 and a 35.13% net profit margin on its 2025 full-year results.

The CSRC approved Unitree's IPO registration on July 2–3, 2026, in just 104 days — the fastest review under the STAR Market's pre-registration mechanism. The company plans to raise roughly 4.2 billion yuan ($618 million) at an implied valuation of approximately 42 billion yuan, selling at least a 10% stake. Caixin linked the accelerated review to Beijing's effort to channel capital toward strategic technology sectors.

The Q1 profit decline surfaces as Unitree competes on multiple fronts: against Tesla's Optimus, UBTECH's U1 series, and a wave of domestic cross-industry entrants. Founder Wang Xingxing retains 68.78% of voting rights post-IPO. The company shipped 5,500-plus humanoids in 2025 on revenue of 1.69 billion yuan, with more than 40% of that revenue coming from outside China.

Unitree Robotics has cleared the final regulatory gate. China's securities regulator has signed off on the company's STAR Board application, and Unitree is now working through the mechanical end of the process — underwriting syndicate, share price band, and subscription window — for a listing that could land as early as late July, according to South China Morning Post. The offering targets 4.2 billion yuan (approximately $618 million USD) through a minimum 10 percent float, which sets a floor valuation of 42 billion yuan. That floor matters: it will be the first hard public-market number applied to an embodied-AI company in China at a moment when the sector is awash in private capital chasing hypothetical multiples.

Read the prospectus before you read the pitch deck. Unitree's Q1 net profit fell 52.55 percent year-on-year — a number that sits in direct tension with a growth narrative. The company has not obscured this; it appears in its own disclosures. The question for investors subscribing to this offering is whether the decline reflects a deliberate reinvestment cycle or a demand plateau. The proceeds allocation gives a partial answer: funds are earmarked for AI robotic model development, robot-body research, new product lines, and a smart manufacturing base. That is a capital-expenditure story, not a margin story. If you are buying the floor valuation, you are buying the infrastructure buildout, not the current earnings.

The international-revenue figure deserves close attention. Unitree has disclosed that over 40 percent of its revenue already originates outside China. For a hardware company in a sector that Western governments are beginning to scrutinize on supply-chain grounds, that number cuts two ways. It validates commercial traction beyond domestic subsidy-driven demand — a real signal amid a market where many embodied-AI companies remain overwhelmingly dependent on state-linked procurement. But it also introduces a risk surface that STAR Board prospectuses are not structurally designed to foreground: export-control exposure, customer concentration in overseas markets, and potential tariff or licensing headwinds as the geopolitical temperature around dual-use robotics continues to rise.

The STAR Board context is worth holding precisely. Shanghai's technology bourse was designed to list companies that might not meet profitability thresholds on the main board, explicitly prioritizing R&D intensity and strategic-sector positioning. Unitree fits the template. But that design also means the board has historically been a venue where retail-investor enthusiasm for a sector narrative can run ahead of unit economics. The Unitree listing will test whether that dynamic has matured, or whether the humanoid-robot moment replicates the new-energy-vehicle frenzy of 2020–2021, where valuations disconnected from near-term fundamentals before mean-reverting sharply.

Sector valuation benchmarking is the real function of this IPO. Humanoid-robot funding in China has surged across 2024 and into 2025, with dozens of companies raising at private valuations that have no public comparable to anchor them. Once Unitree trades, every subsequent funding round in embodied AI will be priced relative to its public multiple. That is a structural role that exceeds Unitree's own business story. SCMP framed the listing as a test of whether venture capital flooding into Chinese robotics is pricing rationally — which is the right frame, even if the answer won't be legible on listing day.

On the technology side, it is worth noting that Unitree's hardware has recently appeared in research contexts alongside Nvidia's robotics infrastructure, as covered by CNBC. That association matters for the AI-model development line in the proceeds plan: Unitree is positioning itself not merely as a robot manufacturer but as a platform on which third-party AI models are trained and deployed. Whether the prospectus substantiates that positioning with concrete partnership disclosures — or leaves it at the level of strategic intention — is a detail worth pulling from the filing directly.

The AIPM intensity reading of 162 on this story reflects genuine policy-market coupling: the STAR Board listing mechanism, the embodied-AI industrial policy backdrop, and the regulatory sign-off chain are all load-bearing. This is not a company that reached this point despite the policy environment; it reached it because of it. That does not make the business less real, but it does mean the risk factors extend beyond the income statement into the political economy of which sectors Beijing continues to treat as strategic priorities — and which it decides to let normalize.

Watch for: the official prospectus update (招股说明书更新稿) filed to the Shanghai Stock Exchange, which will contain the final price range, the lock-up structure for existing investors, and any updated risk disclosures since the initial submission. The subscription window announcement will follow shortly after. The Q2 earnings disclosure — if timed before or immediately after listing — will be the first live test of whether the Q1 profit decline was a trough or a trend. Track the secondary-market multiple on day one against the 42 billion yuan floor: that spread will set the tone for every private humanoid-robot valuation conversation in China for the rest of 2025.

The South China Morning Post confirmed on Thursday that Unitree Robotics is now finalising its underwriting plan, pricing, and share subscriptions for a potential Shanghai STAR Market debut as early as late July. The company plans to raise 4.2 billion yuan ($618 million) by selling at least 40.4 million shares — a minimum 10% stake — implying a floor valuation of roughly 42 billion yuan ($5.9 billion).

Unitree received CSRC approval for the IPO on July 3, after clearing the Shanghai Stock Exchange listing committee review in just 73 days. Founded in 2016 and based in Hangzhou, the company reported 2025 revenue of 1.69 billion yuan and net income of 280 million yuan — rare profitability in the embodied-AI sector.

Nearly half of IPO proceeds are earmarked for AI model training over three years. Unitree would become the first humanoid robot developer listed on China's domestic A-share market, setting a public valuation benchmark for a sector that has attracted billions in private capital this year.